筛选条件
共查询到1条结果
排序方式
~
Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
期刊： EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021; 6 (3)
Introduction: Dacomitinib is a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). Recent results from ARCHER 105......
